This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Roche, Exelixis Skin Cancer Drug Delays Tumor Progression

07/14/14 - 07:46 AM EDT

Roche intends to seek U.S. approval for cobimetinib later this year.

READ FULL POST

Radient Pharma: RIP

07/08/14 - 09:52 AM EDT

The SEC halts trading in Radient Pharmaceuticals.

READ FULL POST

Provectus Admits Cash Running Low, Financing Coming Soon

07/08/14 - 09:14 AM EDT

Provectus Biopharmaceuticals issued a "CEO Letter" Tuesday regurgitating all the recent spin and ridiculously unrealistic talking points about the company's experimental (but already obsolete) melanoma therapy PV-10.

READ FULL POST

Sarepta's Monday Selloff on New (Old) Worries Addressed

07/07/14 - 02:49 PM EDT

Sarepta is selling off Monday on new worries about eteplirsen efficacy. Of course, these are really just old worries, recycled.

READ FULL POST

Arena CEO Dumps Stock as Share Price, Investor Confidence Slide

07/07/14 - 11:23 AM EDT

Lief's $1.3 million sale of Arena shares was disclosed in an SEC filing last week.

READ FULL POST

Ampio Expects Investors to Wear Beer Goggles Before Reading Eye-Drug Press Release

06/25/14 - 01:05 PM EDT

The hip waders I normally wear for protection from biotech bullshit aren't tall enough to wade through Ampio's current press release. I need a full haz-mat suit.

READ FULL POST

Ohr Pharma Applies a Ton of Lipstick to Squalamine Pig

06/24/14 - 12:07 PM EDT

A phase II study of Squalamine in wet age-related macular degeneration bombed badly.

READ FULL POST

Hospital Doubles Down on Northwest Bio's Cancer Vax Disclosure Criticism

06/23/14 - 09:05 AM EDT

MD Anderson released a statement criticizing Northwest Bio on Friday night after company shareholders and supporters flamed the hospital's Facebook page with hateful comments.

READ FULL POST

Northwest Bio Fails to Refute MD Anderson Rebuke

06/20/14 - 09:41 AM EDT

Conspicuously absent from Northwest Biotherapeutics' press release Friday was any mention of the MD Anderson Cancer Center.

READ FULL POST

Bluebird Bio Higher on Strong Gene Therapy Study Results

06/16/14 - 07:28 AM EDT

Two patients with a serious, inherited blood disorder have been able to stop blood transfusions following a single treatment with an experimental gene therapy developed by Bluebird Bio, according to new but preliminary data presented Saturday.

READ FULL POST

Adam Feuerstein is a senior columnist at TheStreet in charge of covering biotechnology and pharmaceutical stocks.

Feuerstein has been a financial journalist for more than 20 years. He joined TheStreet in 2001, leaving in 2005 for a two-year stint as a biotech analyst for a New York-based investment management firm. Feuerstein rejoined TheStreet in 2007. Prior to his work at TheStreet, Feuerstein wrote about Internet startups and business software for Upside.com. Covering the dot-com boom and bust of the 1990s and early 2000s made Feuerstein very cynical, a trait he applies to great effect by highlighting the often-overlooked risks of biotech stock investing. In what can only be considered a high compliment, a particularly promotional sell-side analyst once warned his clients that Feuerstein "attacks viciously".

Expand Bio +

Feuerstein lives near Boston with his wife, two kids and a yellow lab-golden retriever named Max. When Feuerstein is not writing article and blog posts for TheStreet, he's tweeting. In fact, when Feuerstein is working, he's tweeting. All the time. He also runs, bikes, watches a lot of English soccer matches (Go Spurs!) and loves to cook.

Close Bio -

Markets

DOW 16,805.41 +127.51 0.76%
S&P 500 1,964.58 +13.76 0.71%
NASDAQ 4,483.7150 +30.9230 0.69%

Adam's Tweets

Brokerage Partners

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Breakout Stocks

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs